Loading [MathJax]/jax/output/SVG/jax.js

3.8

CiteScore

2.4

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Jing Gao, Fumihiko Nakamura. Intermediate filaments and their associated molecules[J]. The Journal of Biomedical Research, 2025, 39(3): 242-253. DOI: 10.7555/JBR.38.20240193
Citation: Jing Gao, Fumihiko Nakamura. Intermediate filaments and their associated molecules[J]. The Journal of Biomedical Research, 2025, 39(3): 242-253. DOI: 10.7555/JBR.38.20240193

Intermediate filaments and their associated molecules

More Information
  • Corresponding author:

    Fumihiko Nakamura, School of Pharmaceutical Science and Technology, Tianjin University, 92 Weijin Road, Nankai District, Tianjin 300072, China. E-mail: fnakamura@tju.edu.cn

  • Received Date: July 02, 2024
  • Revised Date: November 22, 2024
  • Accepted Date: November 24, 2024
  • Available Online: November 29, 2024
  • Published Date: February 07, 2025
  • Intermediate filaments (IFs) in human cells are the products of six distinct gene families, all sharing homology in a core rod domain. These IFs assemble into non-polar polymers, providing cytoplasmic and nuclear mechanical support. Recent research has revealed the active and dynamic properties of IFs and their binding partners. This regulation extends beyond cell mechanics to include migration, mechanotransduction, and tumor growth. Therefore, this comprehensive review aims to catalog all human IF genes and IF-associated proteins (IFAPs), detailing their names, sizes, functions, associated human diseases, relevant literature, and links to resources like UniProt and the Protein Atlas database. These links provide access to additional information such as protein structure, subcellular localization, disease-causing mutations, and pathology. Using this catalog, we will provide an overview of the current understanding of the biological functions of IFs and IFAPs. This overview is crucial for identifying gaps in their characterization and understanding IF-mediated mechanotransduction. Additionally, we will consider potential future research directions.

  • Anesthesia decisions during surgery involve controlling and maintaining a patient's anesthetic depth, blood pressures and heart rate, among many other conditions. This decision process relies on sound experience of estimating the impact of the drug inputs on the patient outcomes. Accurate estimation of such drug impacts is difficult due to several factors[]: typically, an anesthesia drug can affect multiple outcomes; the same drug can have differing impacts on different patients; the impacts can be altered by surgical types, procedures, stages, and patient conditions; drug-to-drug interactions can influence patient outcomes. For anesthesiologists, management of such parameters on daily basis with accuracy and safety significantly depends on training and experience. Based on our increasing knowledge of drug interactions, it is essential to identify measurable relationships between drug administration and corresponding patient outcomes in a more accurate, objective, and reliable format[].

    Advanced information processing technology can be of great value in this pursuit. For instance, mathematical models can be developed and embedded into anesthesia monitoring systems so that in addition to "monitoring" the current status of a patient, they also can provide a prediction of the patient outcomes in the near-future. Artificial intelligence (AI) techniques and machine learning are also highly suitable in this application since they can use real-time observed data to modify models so that the models can become individualized to the specific patient, and the given type and stage of the surgery.

    We report here an effort in developing such a new technology. The core of this technology is a data-based mathematics function model that relates multiple drugs and their interactions to several essential predictive outcomes of surgical patients in the near-future. This predictive capability can then be employed to display the patient's current status along with predictive near-future outcome trajectories. When a drug infusion rate is modified, its estimated impact can be immediately displayed. As a result, if a specifically targeted anesthesia depth or blood pressure level is required, this function can be used to display a computer-assisted "trial" on the system to ensure that the targeted factors can be achieved within required timeframes before the actual drug is administered to the patient.

    It is noted that the importance of outcome prediction has been recognized in many procedures in anesthesiology and several scoring methods were employed, including Surgical Apgar[], Risk Stratification Tools for predicting morbidity and mortality[], and Preoperative Score for predicting postoperative mortality[]. Computer-assisted outcome prediction and decision assistance are more challenging, and have attracted more attention. Trauma resuscitation errors and their corrections were investigated with AI technology[]. General discussions on feasibility of AI technology for automated anesthesia drug delivery were reported[]. These studies have different focuses, use different methods, and report different results in this paper.

    The study was approved by the appropriate Institutional Review Board and written informed consents were obtained from all subjects[]. We selected a patient population between 20 and 70 years of age (n=7), undergoing upper extremity arteria-venous fistula placement or thrombectomy, under intravenous unconscious sedation. Prior to surgery each patient was given 1 mg of Midazolam Ⅳ, taken to the operating room, and equipped with a bispectral (BIS) monitor (Aspect Medical Devices, Inc.), noninvasive blood pressure (BP) cuff, and pulse oximeter. BIS (streamed continuously) and BP (measured every three minutes) data were used in this study. As the interaction between BIS depth and BP are commonly observed patient data in anesthesia administration, we selected these two parameters as a suitable platform to start and to potentially expand to include others such as heart rate, etc. The data from each patient is divided into two time segments with the first time interval a duration of 30%–50% of the entire data collection time. The first segment is used to establish the model, namely determining the model parameters. The second time segment serves as an independent data for validation. The model fitness is evaluated by comparing the data and the model output for the entire time interval.

    The patient was given 1 –2 μg/kg of bolus Ⅳ fentanyl at the beginning of the surgery and a 1 μg/kg bolus during the surgery, if required. The patient started on intravenous propofol pump at a rate of 50 μg/(kg·minute) and titrated as required during the surgery. A BIS sensor was placed on the patient's forehead before administering anesthesia to the patient. The sensor is connected to the BIS monitor, which in turn was connected to a computer to allow continuous recording and saving of the BIS values. A baseline BIS value of at least 90 is recorded before the administration of anesthesia. All measured heart rates and blood pressures values were entered and saved manually into the computer every three minutes and following any bolus administration. The propofol rate, any changes made to the propofol rate, and any propofol or fentanyl bolus given are also transmitted to the computer model. Data from seven patients were recorded. The BIS range from 0 (no or minimal brain activity) to 100 (patient fully awake and aware), is set by the device manufacturer. As a data collection system, the internal BP limits in the computer system is set on a wide range so as not to disturb or affect data entry. Data for each patient were reviewed by an experienced anesthesiologist for any possible anomalies or errors.

    The core function of this new monitoring technology is framed in establishing reliable embedded computer modelling that can directly correlate the drug or procedure inputs to outcomes in a surgery or procedure. The model structure must be capable of capturing the essential features of a patient's response to the drugs in such a manner that it is able to calculate how the past and current drug infusion rates will result in outcome changes in the immediate future. The model must be tunable to fit specific patient parameters into a varied range of surgical procedures. Here the capability of "AI" is used in the broad sense in which the model parameters are learned from data by certain identification or learning algorithms.

    The function modules of this technology are depicted in Fig. 1. The drug infusion data and patient outcomes were measured by the medical devices, and streamed to the computer for processing. The computer model inputs further patient and surgical information to develop short-term predictive outcomes. The display module shows both the current status and predicted outcomes on the screen with both numerical values and graphical trend curves. Fig. 2 is a collaborative display of anesthesia depth (BIS) and blood pressure. The system additionally contains a decision-assistant function module that allows the anesthesiologist to enter planned drug modifications and the system to generate a predicted impact of such changes. Tuning such modifications can allow the anesthesiologist to develop suitable scenarios to have patient outcomes designed to achieve desired target values at specific times.

    Figure 1. The function modules of the integrated predictive anesthesia monitor where drug infusion data and patient outcomes are measured and streamed to the computer for processing.
    Figure  1.  The function modules of the integrated predictive anesthesia monitor where drug infusion data and patient outcomes are measured and streamed to the computer for processing.
    The computer model inputs further patient and surgical information to develop short-term predictive outcomes. The display module shows both the current status and predicted outcomes on the screen with both numerical values and graphical trend curves.
    Figure 2. Graphical illustration on how the integrated predictive anesthesia monitor can collaboratively display anesthesia depth (BIS) and blood pressure (BP).
    Figure  2.  Graphical illustration on how the integrated predictive anesthesia monitor can collaboratively display anesthesia depth (BIS) and blood pressure (BP).

    To make the model account for patient uniqueness, the learning function uses the observed data to tune the model parameters, leading to a data-based learning capability. In our early work[], a specially designed computer monitoring system was developed to record multi-drug-multiple-outcome data. The data observed a clear correlated outcome response to propofol titration, bolus injection and fentanyl injection: the anesthesia drugs lower the patient BIS values, depress blood pressure, and result in higher heart rate fluctuations.

    To capture such dynamic relationships, we are developing an enhanced modelling technique which involves the following function modules: (1) The drug input function module to represent the drug-administering system, injection pathway, and propagation to the blood; (2) The dynamic system module to capture the common feature of initial delay and gradual impact of the drug on outcomes; (3) The multi-output function module to model the impact of the drug on each considered outcome.

    The basic model structure is called a "Wiener Model"[,], which relates an input to an output and contains three generic blocks: time delay, dynamic delay, and sensitivity function. It can be used for different inputs and outputs such as propofol-to-BIS relationship. For each application, the parameters will be different in different patients, which are estimated by data.

    This model structure was further expanded to include multiple inputs and multiple outputs, and called a multi-input-multi-output Hammerstein-Weiner model in engineering. It extends our previous work of using single-input-single-output Wiener models[,] which do not involve the drug input function, to the multi-drug-multi-outcome framework here. By using the simplified but representative dynamics and functions to represent these relationships, we ensure that the model contains only a relatively small set of parameters that can be updated and learned in real time during a surgery.

    Our approach for determining the parameter values is data-based learning and system identification. In our early work[], we used a special identification algorithm to learn model parameters. In this approach, we first use the patient condition and population-based model as the initial parameter values. After the drug administration is performed, the system starts to receive data on the drug infusion and the patient outcomes, which are used to modify the parameter values. The algorithms used to perform this task are called system identification algorithms.

    The distinct advantages and contributions of our approach are in the following aspects: (1) Since simplified dynamic and function models are used, less data is required to update the parameters so that the model can more rapidly capture the salient characteristics of a specific patient, under a specific surgery, at a specific time; (2) By including the drug input functions, our model can capture data from diversified medical devices by multiple manufacturers with multiple differing device features; (3) By including multiple drugs and multiple outcomes in a unified model, we can represent interactions of drugs and their correlated impact on patient outcomes under a unified monitor system.

    In our study, we used a simple-structured dynamic model that mainly captured the drug impact in the following aspects: the effects of drug changes on the BIS and BP, the time delay before the initial visible response, and the response speed of the drug effect on the BIS and BP. Mathematically, this can be written as a three-component cascaded system: a time delay of τ seconds written as eτs, a first-order dynamics of time constant T written as 11+Ts, and a nonlinear sensitivity function f(x) where x is the drug infusion rate. For convenience of implementation, f(x) can be a simple polynomial whose coefficients must be learned from data. Also, each model channel was modeled differently. For example, the channels from the fentanyl bolus injection, the propofol bolus injection, and the propofol titration to the BIS and BP, were collected on separate channels. After selecting the model structure, the data were then used to identify or learn model parameters. The model's usefulness was evaluated by its predictive capability on the measured BIS and BP values.

    As shown in Fig. 3, with recorded data and our system's predicted outcome values, BIS values can be affected by many unknown factors, such as surgery stimulation, and body movement, among many others. The system's capability was reflected by its prediction of the main trend of BIS values as responses to drug administration. The curves showed desirable features of the system. The BP data were collected every three minutes. The curves outline that propofol affected the BP, but with slightly less impact than the fentanyl injection.

    Figure 3. The recorded data and predicted outcome values from the integrated predictive anesthesia monitor system.
    Figure  3.  The recorded data and predicted outcome values from the integrated predictive anesthesia monitor system.

    There have been extensive efforts in studying automated anesthesia administration by using feedback control techniques[]. These population-based models lack the ability of "learning" in real time to generate patient-specific models. The multi-outcome predictive monitoring technique described here is a fundamental improvement on the current anesthesia monitoring technology by providing critical future-impact information, manageable reliability, and useful decision assistance. The main ideas of using mathematics models, signal processing, and individualized management to improve anesthesia care have been used in other related areas of anesthesiology[]. This report highlights a promising approach to addressing several critical requirements for such a new technology: simple and reliable models, data-based and individualized patient outcome monitoring and prediction, and learning capability.

    This research was funded by the National Natural Science Foundation of China (Grant No. 32070777 to F.N.).

    None.

    CLC number: R329.28, Document code: A

    The authors reported no conflict of interests.

  • [1]
    Chakraborty S, Jasnin M, Baumeister W. Three-dimensional organization of the cytoskeleton: a cryo-electron tomography perspective[J]. Protein Sci, 2020, 29(6): 1302–1320. doi: 10.1002/pro.3858
    [2]
    Lorenz C, Köster S. Multiscale architecture: mechanics of composite cytoskeletal networks[J]. Biophys Rev (Melville), 2022, 3(3): 031304. doi: 10.1063/5.0099405
    [3]
    Doganyigit Z, Eroglu E, Okan A. Intermediate filament proteins are reliable immunohistological biomarkers to help diagnose multiple tissue-specific diseases[J]. Anat Histol Embryol, 2023, 52(5): 655–672. doi: 10.1111/ahe.12937
    [4]
    Barritt J, King AT, Pickard JN. The effects of cystine diet on keratin composition in rabbit wool[J]. Biochem J, 1930, 24(4): 1061–1065. doi: 10.1042/bj0241061
    [5]
    Palay SL, Palade GE. The fine structure of neurons[J]. J Biophys Biochem Cytol, 1955, 1(1): 69–88. doi: 10.1083/jcb.1.1.69
    [6]
    Ishikawa H, Bischoff R, Holtzer H. Formation of arrowhead complexes with heavy meromyosin in a variety of cell types[J]. J Cell Biol, 1969, 43(2): 312–328. doi: 10.1083/jcb.43.2.312
    [7]
    Franke WW, Schmid E, Osborn M, et al. Different intermediate-sized filaments distinguished by immunofluorescence microscopy[J]. Proc Natl Acad Sci U S A, 1978, 75(10): 5034–5038. doi: 10.1073/pnas.75.10.5034
    [8]
    Schmid E, Tapscott S, Bennett GS, et al. Differential location of different types of intermediate-sized filaments in various tissues of the chicken embryo[J]. Differentiation, 1979, 15(1): 27–40. https://pubmed.ncbi.nlm.nih.gov/93557/
    [9]
    Goldmann WH. Intermediate filaments and cellular mechanics[J]. Cell Biol Int, 2018, 42(2): 132–138. doi: 10.1002/cbin.10879
    [10]
    Gao J, Nakamura F. Actin-associated proteins and small molecules targeting the actin cytoskeleton[J]. Int J Mol Sci, 2022, 23(4): 2118. doi: 10.3390/ijms23042118
    [11]
    Peng N, Nakamura F. Microtubule-associated proteins and enzymes modifying tubulin[J]. Cytoskeleton (Hoboken), 2023, 80(3-4): 60–76. doi: 10.1002/cm.21748
    [12]
    Bott CJ, Winckler B. Intermediate filaments in developing neurons: beyond structure[J]. Cytoskeleton (Hoboken), 2020, 77(3-4): 110–128. doi: 10.1002/cm.21597
    [13]
    Dutour-Provenzano G, Etienne-Manneville S. Intermediate filaments[J]. Curr Biol, 2021, 31(10): R522–R529. doi: 10.1016/j.cub.2021.04.011
    [14]
    Eldirany SA, Lomakin IB, Ho M, et al. Recent insight into intermediate filament structure[J]. Curr Opin Cell Biol, 2021, 68: 132–143. doi: 10.1016/j.ceb.2020.10.001
    [15]
    Sjöqvist M, Antfolk D, Suarez-Rodriguez F, et al. From structural resilience to cell specification-intermediate filaments as regulators of cell fate[J]. FASEB J, 2021, 35(1): e21182. https://pubmed.ncbi.nlm.nih.gov/33205514/
    [16]
    Romano R, Del Fiore VS, Bucci C. Role of the intermediate filament protein peripherin in health and disease[J]. Int J Mol Sci, 2022, 23(23): 15416. doi: 10.3390/ijms232315416
    [17]
    Infante E, Etienne-Manneville S. Intermediate filaments: integration of cell mechanical properties during migration[J]. Front Cell Dev Biol, 2022, 10: 951816. doi: 10.3389/fcell.2022.951816
    [18]
    Coulombe PA, Pineda CM, Jacob JT, et al. Nuclear roles for non-lamin intermediate filament proteins[J]. Curr Opin Cell Biol, 2024, 86: 102303. doi: 10.1016/j.ceb.2023.102303
    [19]
    Pogoda K, Janmey PA. Transmit and protect: the mechanical functions of intermediate filaments[J]. Curr Opin Cell Biol, 2023, 85: 102281. doi: 10.1016/j.ceb.2023.102281
    [20]
    Schwarz N, Leube RE. Plasticity of cytoplasmic intermediate filament architecture determines cellular functions[J]. Curr Opin Cell Biol, 2023, 85: 102270. doi: 10.1016/j.ceb.2023.102270
    [21]
    Utsunomiya H, Fujita M, Naito F, et al. Cell cycle-dependent dynamics of a plant intermediate filament motif protein with intracellular localization related to microtubules[J]. Protoplasma, 2020, 257(5): 1387–1400. doi: 10.1007/s00709-020-01512-1
    [22]
    Shymanovich T, Vandenbrink JP, Herranz R, et al. Spaceflight studies identify a gene encoding an intermediate filament involved in tropism pathways[J]. Plant Physiol Biochem, 2022, 171: 191–200. doi: 10.1016/j.plaphy.2021.12.039
    [23]
    Jacob JT, Coulombe PA, Kwan R, et al. Types Ⅰ and Ⅱ keratin intermediate filaments[J]. Cold Spring Harb Perspect Biol, 2018, 10(4): a018275. doi: 10.1101/cshperspect.a018275
    [24]
    Mohamad J, Sarig O, Beattie P, et al. A unique skin phenotype resulting from a large heterozygous deletion spanning six keratin genes[J]. Br J Dermatol, 2022, 187(5): 773–777. doi: 10.1111/bjd.21766
    [25]
    Li P, Rietscher K, Jopp H, et al. Posttranslational modifications of keratins and their associated proteins as therapeutic targets in keratin diseases[J]. Curr Opin Cell Biol, 2023, 85: 102264. doi: 10.1016/j.ceb.2023.102264
    [26]
    Kotalevskaya YY, Stepanov VA. Molecular genetic basis of epidermolysis bullosa[J]. Vavilovskii Zhurnal Genet Selektsii, 2023, 27(1): 18–27. https://pubmed.ncbi.nlm.nih.gov/36923479/
    [27]
    Walko G, Castañón MJ, Wiche G. Molecular architecture and function of the hemidesmosome[J]. Cell Tissue Res, 2015, 360(3): 529–544. doi: 10.1007/s00441-015-2216-6
    [28]
    Evtushenko NA, Beilin AK, Kosykh AV, et al. Keratins as an inflammation trigger point in epidermolysis bullosa simplex[J]. Int J Mol Sci, 2021, 22(22): 12446. doi: 10.3390/ijms222212446
    [29]
    Chen F, Yao L, Zhang X, et al. Damaged keratin filament network caused by KRT5 mutations in localized recessive epidermolysis bullosa simplex[J]. Front Genet, 2021, 12: 736610. doi: 10.3389/fgene.2021.736610
    [30]
    Has C, Fischer J. Inherited epidermolysis bullosa: new diagnostics and new clinical phenotypes[J]. Exp Dermatol, 2019, 28(10): 1146–1152. doi: 10.1111/exd.13668
    [31]
    DeStefano GM, Christiano AM. The genetics of human skin disease[J]. Cold Spring Harb Perspect Med, 2014, 4(10): a015172. doi: 10.1101/cshperspect.a015172
    [32]
    Leube RE, Schwarz N. Current mysteries of pachyonychia congenita[J]. Br J Dermatol, 2020, 182(3): 525–526. doi: 10.1111/bjd.18688
    [33]
    Goldfarb LG, Olivé M, Vicart P, et al. Intermediate filament diseases: desminopathy[M]//Laing NG. The Sarcomere and Skeletal Muscle Disease. New York: Springer, 2008: 131–164.
    [34]
    Kubánek M, Schimerová T, Piherová L, et al. Desminopathy: novel desmin variants, a new cardiac phenotype, and further evidence for secondary mitochondrial dysfunction[J]. J Clin Med, 2020, 9(4): 937. doi: 10.3390/jcm9040937
    [35]
    Su W, van Wijk SW, Brundel BJJM. Desmin variants: trigger for cardiac arrhythmias?[J]. Front Cell Dev Biol, 2022, 10: 986718. doi: 10.3389/fcell.2022.986718
    [36]
    Marunouchi T, Inomata S, Sanbe A, et al. Protective effect of geranylgeranylacetone via enhanced induction of HSPB1 and HSPB8 in mitochondria of the failing heart following myocardial infarction in rats[J]. Eur J Pharmacol, 2014, 730: 140–147. doi: 10.1016/j.ejphar.2014.02.037
    [37]
    Sanbe A, Daicho T, Mizutani R, et al. Protective effect of geranylgeranylacetone via enhancement of HSPB8 induction in desmin-related cardiomyopathy[J]. PLoS One, 2009, 4(4): e5351. doi: 10.1371/journal.pone.0005351
    [38]
    Viedma-Poyatos Á, Pajares MA, Pérez-Sala D. Type Ⅲ intermediate filaments as targets and effectors of electrophiles and oxidants[J]. Redox Biol, 2020, 36: 101582. doi: 10.1016/j.redox.2020.101582
    [39]
    Pérez-Sala D, Quinlan RA. The redox-responsive roles of intermediate filaments in cellular stress detection, integration and mitigation[J]. Curr Opin Cell Biol, 2024, 86: 102283. doi: 10.1016/j.ceb.2023.102283
    [40]
    Botha CJ, Mathe YZ, Ferreira GCH, et al. Cytotoxicity of the sesquiterpene lactones, ivalin and parthenolide in murine muscle cell lines and their effect on desmin, a cytoskeletal intermediate filament[J]. Toxins (Basel), 2020, 12(7): 459. doi: 10.3390/toxins12070459
    [41]
    Zhao J, Liem RK. α-Internexin and peripherin: expression, assembly, functions, and roles in disease[J]. Methods Enzymol, 2016, 568: 477–507. https://www.sciencedirect.com/unsupported_browser
    [42]
    Jaramillo-Rangel G, Chávez-Briones MDL, Ancer-Arellano A, et al. Nestin-expressing cells in the lung: the bad and the good parts[J]. Cells, 2021, 10(12): 3413. doi: 10.3390/cells10123413
    [43]
    Maggi L, Mavroidis M, Psarras S, et al. Skeletal and cardiac muscle disorders caused by mutations in genes encoding intermediate filament proteins[J]. Int J Mol Sci, 2021, 22(8): 4256. doi: 10.3390/ijms22084256
    [44]
    Ducray F, Criniere E, Idbaih A, et al. α-Internexin expression identifies 1p19q codeleted gliomas[J]. Neurology, 2009, 72(2): 156–161. doi: 10.1212/01.wnl.0000339055.64476.cb
    [45]
    Yuan A, Rao MV, Veeranna, et al. Neurofilaments and neurofilament proteins in health and disease[J]. Cold Spring Harb Perspect Biol, 2017, 9(4): a018309. doi: 10.1101/cshperspect.a018309
    [46]
    Kotaich F, Caillol D, Bomont P. Neurofilaments in health and Charcot-Marie-Tooth disease[J]. Front Cell Dev Biol, 2023, 11: 1275155. doi: 10.3389/fcell.2023.1275155
    [47]
    Stone EJ, Kolb SJ, Brown A. A review and analysis of the clinical literature on Charcot-Marie-Tooth disease caused by mutations in neurofilament protein L[J]. Cytoskeleton (Hoboken), 2021, 78(3): 97–110. doi: 10.1002/cm.21676
    [48]
    Pisciotta C, Pareyson D. CMT2CC associated with NEFH mutations: a predominantly motor neuronopathy[J]. J Neurol Neurosurg Psychiatry, 2022, 93(1): 1. https://pubmed.ncbi.nlm.nih.gov/34518332/
    [49]
    Cortese A, Wilcox JE, Polke JM, et al. Targeted next-generation sequencing panels in the diagnosis of Charcot-Marie-Tooth disease[J]. Neurology, 2020, 94(1): e51–e61. https://pubmed.ncbi.nlm.nih.gov/31827005/
    [50]
    Stone EJ, Uchida A, Brown A. Charcot-Marie-Tooth disease Type 2E/1F mutant neurofilament proteins assemble into neurofilaments[J]. Cytoskeleton (Hoboken), 2019, 76(7-8): 423–439. doi: 10.1002/cm.21566
    [51]
    Nowogrodzka K, Jankowska-Konsur A. Emerging biomarker in carcinogenesis. Focus on nestin[J]. Postepy Dermatol Alergol, 2022, 39(6): 1001–1007. doi: 10.5114/ada.2022.122599
    [52]
    Russell MA. Synemin redefined: multiple binding partners results in multifunctionality[J]. Front Cell Dev Biol, 2020, 8: 159. doi: 10.3389/fcell.2020.00159
    [53]
    Paulin D, Hovhannisyan Y, Kasakyan S, et al. Synemin-related skeletal and cardiac myopathies: an overview of pathogenic variants[J]. Am J Physiol Cell Physiol, 2020, 318(4): C709–C718. doi: 10.1152/ajpcell.00485.2019
    [54]
    Song S, Landsbury A, Dahm R, et al. Functions of the intermediate filament cytoskeleton in the eye lens[J]. J Clin Invest, 2009, 119(7): 1837–1848. doi: 10.1172/JCI38277
    [55]
    Wang H, Zhang T, Wu D, et al. A novel beaded filament structural protein 1 (BFSP1) gene mutation associated with autosomal dominant congenital cataract in a Chinese family[J]. Mol Vis, 2013, 19: 2590–2595. https://pubmed.ncbi.nlm.nih.gov/24379646/
    [56]
    Liu Q, Wang K, Zhu S. A novel p.G112E mutation in BFSP2 associated with autosomal dominant pulverulent cataract with sutural opacities[J]. Curr Eye Res, 2014, 39(10): 1013–1019. doi: 10.3109/02713683.2014.891749
    [57]
    Wang H, Ouyang G, Zhu Y. D348N mutation of BFSP1 gene in congenital cataract: it does matter[J]. Cell Biochem Biophys, 2023, 81(4): 757–763. doi: 10.1007/s12013-023-01169-6
    [58]
    Cvekl A, Camerino MJ. Generation of lens progenitor cells and lentoid bodies from pluripotent stem cells: novel tools for human lens development and ocular disease etiology[J]. Cells, 2022, 11(21): 3516. doi: 10.3390/cells11213516
    [59]
    Marcelot A, Worman HJ, Zinn-Justin S. Protein structural and mechanistic basis of progeroid laminopathies[J]. FEBS J, 2021, 288(9): 2757–2772. doi: 10.1111/febs.15526
    [60]
    Shah PP, Santini GT, Shen KM, et al. InterLINCing chromatin organization and mechanobiology in laminopathies[J]. Curr Cardiol Rep, 2023, 25(5): 307–314. doi: 10.1007/s11886-023-01853-2
    [61]
    Wong X, Stewart CL. The laminopathies and the insights they provide into the structural and functional organization of the nucleus[J]. Annu Rev Genomics Hum Genet, 2020, 21: 263–288. doi: 10.1146/annurev-genom-121219-083616
    [62]
    Malashicheva A, Perepelina K. Diversity of nuclear lamin A/C action as a key to tissue-specific regulation of cellular identity in health and disease[J]. Front Cell Dev Biol, 2021, 9: 761469. doi: 10.3389/fcell.2021.761469
    [63]
    Yamada S, Ko T, Ito M, et al. TEAD1 trapping by the Q353R-Lamin A/C causes dilated cardiomyopathy[J]. Sci Adv, 2023, 9(15): eade7047. doi: 10.1126/sciadv.ade7047
    [64]
    Infante A, Rodríguez CI. Pathologically relevant prelamin a interactions with transcription factors[J]. Methods Enzymol, 2016, 569: 485–501. https://pubmed.ncbi.nlm.nih.gov/26778572/
    [65]
    Evangelisti C, Rusciano I, Mongiorgi S, et al. The wide and growing range of lamin B-related diseases: from laminopathies to cancer[J]. Cell Mol Life Sci, 2022, 79(2): 126. doi: 10.1007/s00018-021-04084-2
    [66]
    Samen U, Eikmanns BJ, Reinscheid DJ, et al. The surface protein Srr-1 of Streptococcus agalactiae binds human keratin 4 and promotes adherence to epithelial HEp-2 cells[J]. Infect Immun, 2007, 75(11): 5405–5414. doi: 10.1128/IAI.00717-07
    [67]
    Das S, Ravi V, Desai A. Japanese encephalitis virus interacts with vimentin to facilitate its entry into porcine kidney cell line[J]. Virus Res, 2011, 160(1-2): 404–408. doi: 10.1016/j.virusres.2011.06.001
    [68]
    Deng L, Spencer BL, Holmes JA, et al. The Group B Streptococcal surface antigen Ⅰ/Ⅱ protein, BspC, interacts with host vimentin to promote adherence to brain endothelium and inflammation during the pathogenesis of meningitis[J]. PLoS Pathog, 2019, 15(6): e1007848. doi: 10.1371/journal.ppat.1007848
    [69]
    Ma X, Ling Y, Li P, et al. Cellular vimentin interacts with foot-and-mouth disease virus nonstructural protein 3A and negatively modulates viral replication[J]. J Virol, 2020, 94(16): e00273–20. https://pubmed.ncbi.nlm.nih.gov/32493819/
    [70]
    Wang A, Liu X, Heckmann A, et al. A Trichinella spiralis new born larvae-specific protein, Ts-NBL1, interacts with host's cell vimentin[J]. Parasitol Res, 2022, 121(5): 1369–1378. doi: 10.1007/s00436-022-07479-7
    [71]
    Deptuła P, Fiedoruk K, Wasilewska M, et al. Physicochemical nature of SARS-CoV-2 spike protein binding to human vimentin[J]. ACS Appl Mater Interfaces, 2023, 15(28): 34172–34180. doi: 10.1021/acsami.3c03347
    [72]
    Zhang Y, Zhao S, Li Y, et al. Host cytoskeletal vimentin serves as a structural organizer and an RNA-binding protein regulator to facilitate Zika viral replication[J]. Proc Natl Acad Sci U S A, 2022, 119(8): e2113909119. doi: 10.1073/pnas.2113909119
    [73]
    Risinger AL, Du L. Targeting and extending the eukaryotic druggable genome with natural products: cytoskeletal targets of natural products[J]. Nat Prod Rep, 2020, 37(5): 634–652. doi: 10.1039/C9NP00053D
    [74]
    Kerns ML, DePianto D, Dinkova-Kostova AT, et al. Reprogramming of keratin biosynthesis by sulforaphane restores skin integrity in epidermolysis bullosa simplex[J]. Proc Natl Acad Sci U S A, 2007, 104(36): 14460–14465. doi: 10.1073/pnas.0706486104
    [75]
    Virtanen M, Gedde-Dahl T Jr, Mörk NJ, et al. Phenotypic/genotypic correlations in patients with epidermolytic hyperkeratosis and the effects of retinoid therapy on keratin expression[J]. Acta Derm Venereol, 2001, 81(3): 163–170. doi: 10.1080/000155501750376221
    [76]
    Zieman AG, Poll BG, Ma J, et al. Altered keratinocyte differentiation is an early driver of keratin mutation-based palmoplantar keratoderma[J]. Hum Mol Genet, 2019, 28(13): 2255–2270. doi: 10.1093/hmg/ddz050
    [77]
    Kim KH, Jung JH, Chung WS, et al. Ferulic acid induces keratin 6α via inhibition of nuclear β-catenin accumulation and activation of Nrf2 in wound-induced inflammation[J]. Biomedicines, 2021, 9(5): 459. doi: 10.3390/biomedicines9050459
    [78]
    Kwan R, Looi K, Omary MB. Absence of keratins 8 and 18 in rodent epithelial cell lines associates with keratin gene mutation and DNA methylation: cell line selective effects on cell invasion[J]. Exp Cell Res, 2015, 335(1): 12–22. doi: 10.1016/j.yexcr.2015.04.003
    [79]
    Rietscher K, Jahnke HG, Rübsam M, et al. Kinase inhibition by PKC412 prevents epithelial sheet damage in autosomal dominant epidermolysis bullosa simplex through keratin and cell contact stabilization[J]. J Invest Dermatol, 2022, 142(12): 3282–3293. doi: 10.1016/j.jid.2022.05.1088
    [80]
    Ziaei E, de Paiva IM, Yao SJ, et al. Peptide-drug conjugate targeting keratin 1 inhibits triple-negative breast cancer in mice[J]. Mol Pharm, 2023, 20(7): 3570–3577. doi: 10.1021/acs.molpharmaceut.3c00189
    [81]
    Lee GH, Lekwuttikarn R, Tafoya E, et al. Transcriptomic repositioning analysis identifies mTOR inhibitor as potential therapy for epidermolysis bullosa simplex[J]. J Invest Dermatol, 2022, 142(2): 382–389. doi: 10.1016/j.jid.2021.07.170
    [82]
    Cabet E, Batonnet-Pichon S, Delort F, et al. Antioxidant treatment and induction of autophagy cooperate to reduce desmin aggregation in a cellular model of desminopathy[J]. PLoS One, 2015, 10(9): e0137009. doi: 10.1371/journal.pone.0137009
    [83]
    Bachetti T, Zanni ED, Adamo A, et al. Beneficial effect of phenytoin and carbamazepine on GFAP gene expression and mutant GFAP folding in a cellular model of Alexander's disease[J]. Front Pharmacol, 2021, 12: 723218. doi: 10.3389/fphar.2021.723218
    [84]
    Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy[J]. Cell Mol Life Sci, 2011, 68(18): 3033–3046. doi: 10.1007/s00018-011-0735-1
    [85]
    Bollong MJ, Pietilä M, Pearson AD, et al. A vimentin binding small molecule leads to mitotic disruption in mesenchymal cancers[J]. Proc Natl Acad Sci U S A, 2017, 114(46): E9903–E9912. doi: 10.1073/pnas.1716009114
    [86]
    Ramos I, Stamatakis K, Oeste CL, et al. Vimentin as a multifaceted player and potential therapeutic target in viral infections[J]. Int J Mol Sci, 2020, 21(13): 4675. doi: 10.3390/ijms21134675
    [87]
    Bargagna-Mohan P, Hamza A, Kim YE, et al. The tumor inhibitor and antiangiogenic agent Withaferin A targets the intermediate filament protein vimentin[J]. Chem Biol, 2007, 14(6): 623–634. doi: 10.1016/j.chembiol.2007.04.010
    [88]
    Mohan R, Bargagna-Mohan P. The use of Withaferin A to study intermediate filaments[J]. Methods Enzymol, 2016, 568: 187–218. https://pubmed.ncbi.nlm.nih.gov/26795472/
    [89]
    Bargagna-Mohan P, Paranthan RR, Hamza A, et al. Withaferin A targets intermediate filaments glial fibrillary acidic protein and vimentin in a model of retinal gliosis[J]. J Biol Chem, 2010, 285(10): 7657–7669. doi: 10.1074/jbc.M109.093765
    [90]
    Bargagna-Mohan P, Paranthan RR, Hamza A, et al. Corneal antifibrotic switch identified in genetic and pharmacological deficiency of vimentin[J]. J Biol Chem, 2012, 287(2): 989–1006. doi: 10.1074/jbc.M111.297150
    [91]
    Thaiparambil JT, Bender L, Ganesh T, et al. Withaferin A inhibits breast cancer invasion and metastasis at sub-cytotoxic doses by inducing vimentin disassembly and serine 56 phosphorylation[J]. Int J Cancer, 2011, 129(11): 2744–2755. doi: 10.1002/ijc.25938
    [92]
    de Pablo Y, Chen M, Möllerström E, et al. Drugs targeting intermediate filaments can improve neurosupportive properties of astrocytes[J]. Brain Res Bull, 2018, 136: 130–138. doi: 10.1016/j.brainresbull.2017.01.021
    [93]
    Kaschula CH, Tuveri R, Ngarande E, et al. The garlic compound ajoene covalently binds vimentin, disrupts the vimentin network and exerts anti-metastatic activity in cancer cells[J]. BMC Cancer, 2019, 19(1): 248. doi: 10.1186/s12885-019-5388-8
    [94]
    Trogden KP, Battaglia RA, Kabiraj P, et al. An image-based small-molecule screen identifies vimentin as a pharmacologically relevant target of simvastatin in cancer cells[J]. FASEB J, 2018, 32(5): 2841–2854. doi: 10.1096/fj.201700663R
    [95]
    Kim HR, Warrington SJ, López-Guajardo A, et al. ALD-R491 regulates vimentin filament stability and solubility, cell contractile force, cell migration speed and directionality[J]. Front Cell Dev Biol, 2022, 10: 926283. doi: 10.3389/fcell.2022.926283
    [96]
    Rezaeianpour M, Mazidi SM, Nami R, et al. Vimentin-targeted radiopeptide 99mTc-HYNIC-(tricine/EDDA)-VNTANST: a promising drug for pulmonary fibrosis imaging[J]. Nucl Med Commun, 2023, 44(9): 777–787. doi: 10.1097/MNM.0000000000001724
    [97]
    He S, Lin J, Lin L, et al. Shikonin-mediated inhibition of nestin affects hypoxia-induced proliferation of pulmonary artery smooth muscle cells[J]. Mol Med Rep, 2018, 18(3): 3476–3482. https://pubmed.ncbi.nlm.nih.gov/30066896/
    [98]
    Feng X, Han H, Guo Y, et al. LncRNA ENST869 targeting Nestin transcriptional region to affect the pharmacological effects of chidamide in breast cancer cells[J]. Front Oncol, 2022, 12: 874343. doi: 10.3389/fonc.2022.874343
    [99]
    Lee SJ, Jung YS, Yoon MH, et al. Interruption of progerin-lamin A/C binding ameliorates Hutchinson-Gilford progeria syndrome phenotype[J]. J Clin Invest, 2016, 126(10): 3879–3893. doi: 10.1172/JCI84164
    [100]
    Kang SM, Yoon MH, Ahn J, et al. Progerinin, an optimized progerin-lamin A binding inhibitor, ameliorates premature senescence phenotypes of Hutchinson-Gilford progeria syndrome[J]. Commun Biol, 2021, 4(1): 5. doi: 10.1038/s42003-020-01540-w
    [101]
    Kang SM, Seo S, Song EJ, et al. Progerinin, an inhibitor of progerin, alleviates cardiac abnormalities in a model mouse of Hutchinson-Gilford progeria syndrome[J]. Cells, 2023, 12(9): 1232. doi: 10.3390/cells12091232
    [102]
    Glynn MW, Glover TW. Incomplete processing of mutant lamin A in Hutchinson-Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition[J]. Hum Mol Genet, 2005, 14(20): 2959–2969. doi: 10.1093/hmg/ddi326
    [103]
    Finley J. Alteration of splice site selection in the LMNA gene and inhibition of progerin production via AMPK activation[J]. Med Hypotheses, 2014, 83(5): 580–587. doi: 10.1016/j.mehy.2014.08.016
    [104]
    Finley J. Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome[J]. Med Hypotheses, 2018, 118: 151–162. doi: 10.1016/j.mehy.2018.06.029
    [105]
    Kim BH, Woo TG, Kang SM, et al. Splicing variants, protein-protein interactions, and drug targeting in Hutchinson-Gilford progeria syndrome and small cell lung cancer[J]. Genes (Basel), 2022, 13(2): 165. doi: 10.3390/genes13020165
    [106]
    Captur G, Arbustini E, Bonne G, et al. Lamin and the heart[J]. Heart, 2018, 104(6): 468–479. doi: 10.1136/heartjnl-2017-312338
    [107]
    Tsai CF, Wu JY, Hsu YW. Protective effects of rosmarinic acid against selenite-induced cataract and oxidative damage in rats[J]. Int J Med Sci, 2019, 16(5): 729–740. doi: 10.7150/ijms.32222
    [108]
    Janmey PA, Euteneuer U, Traub P, et al. Viscoelastic properties of vimentin compared with other filamentous biopolymer networks[J]. J Cell Biol, 1991, 113(1): 155–160. doi: 10.1083/jcb.113.1.155
    [109]
    Huber F, Boire A, López MP, et al. Cytoskeletal crosstalk: when three different personalities team up[J]. Curr Opin Cell Biol, 2015, 32(24): 39–47. doi: 10.1016/j.ceb.2014.10.005
    [110]
    Rölleke U, Kumari P, Meyer R, et al. The unique biomechanics of intermediate filaments – from single filaments to cells and tissues[J]. Curr Opin Cell Biol, 2023, 85: 102263. doi: 10.1016/j.ceb.2023.102263
    [111]
    Wen Q, Janmey PA. Polymer physics of the cytoskeleton[J]. Curr Opin Solid State Mater Sci, 2011, 15(5): 177–182. doi: 10.1016/j.cossms.2011.05.002
    [112]
    Sapra KT, Medalia O. Bend, push, stretch: remarkable structure and mechanics of single intermediate filaments and meshworks[J]. Cells, 2021, 10(8): 1960. doi: 10.3390/cells10081960
    [113]
    van Bodegraven EJ, Etienne-Manneville S. Intermediate filaments from tissue integrity to single molecule mechanics[J]. Cells, 2021, 10(8): 1905. doi: 10.3390/cells10081905
    [114]
    Hu J, Li Y, Hao Y, et al. High stretchability, strength, and toughness of living cells enabled by hyperelastic vimentin intermediate filaments[J]. Proc Natl Acad Sci U S A, 2019, 116(35): 17175–17180. doi: 10.1073/pnas.1903890116
    [115]
    Ackbarow T, Sen D, Thaulow C, et al. Alpha-helical protein networks are self-protective and flaw-tolerant[J]. PLoS One, 2009, 4(6): e6015. doi: 10.1371/journal.pone.0006015
    [116]
    Block J, Witt H, Candelli A, et al. Nonlinear loading-rate-dependent force response of individual vimentin intermediate filaments to applied strain[J]. Phys Rev Lett, 2017, 118(4): 048101. doi: 10.1103/PhysRevLett.118.048101
    [117]
    Johnson CP, Tang HY, Carag C, et al. Forced unfolding of proteins within cells[J]. Science, 2007, 317(5838): 663–666. doi: 10.1126/science.1139857
    [118]
    Fleissner F, Kumar S, Klein N, et al. Tension causes unfolding of intracellular vimentin intermediate filaments[J]. Adv Biosyst, 2020, 4(11): e2000111. doi: 10.1002/adbi.202000111
    [119]
    Seltmann K, Fritsch AW, Käs JA, et al. Keratins significantly contribute to cell stiffness and impact invasive behavior[J]. Proc Natl Acad Sci U S A, 2013, 110(46): 18507–18512. doi: 10.1073/pnas.1310493110
    [120]
    Ramms L, Fabris G, Windoffer R, et al. Keratins as the main component for the mechanical integrity of keratinocytes[J]. Proc Natl Acad Sci U S A, 2013, 110(46): 18513–18518. doi: 10.1073/pnas.1313491110
    [121]
    Charrier EE, Montel L, Asnacios A, et al. The desmin network is a determinant of the cytoplasmic stiffness of myoblasts[J]. Biol Cell, 2018, 110(4): 77–90. doi: 10.1111/boc.201700040
    [122]
    Patteson AE, Vahabikashi A, Pogoda K, et al. Vimentin protects cells against nuclear rupture and DNA damage during migration[J]. J Cell Biol, 2019, 218(12): 4079–4092. doi: 10.1083/jcb.201902046
    [123]
    Laly AC, Sliogeryte K, Pundel OJ, et al. The keratin network of intermediate filaments regulates keratinocyte rigidity sensing and nuclear mechanotransduction[J]. Sci Adv, 2021, 7(5): eabd6187. doi: 10.1126/sciadv.abd6187
    [124]
    Swoger M, Gupta S, Charrier EE, et al. Vimentin intermediate filaments mediate cell morphology on viscoelastic substrates[J]. ACS Appl Bio Mater, 2022, 5(2): 552–561. doi: 10.1021/acsabm.1c01046
    [125]
    Alisafaei F, Mandal K, Saldanha R, et al. Vimentin is a key regulator of cell mechanosensing through opposite actions on actomyosin and microtubule networks[J]. Commun Biol, 2024, 7(1): 658. doi: 10.1038/s42003-024-06366-4
    [126]
    Daday C, Kolšek K, Gräter F. The mechano-sensing role of the unique SH3 insertion in plakin domains revealed by molecular dynamics simulations[J]. Sci Rep, 2017, 7(1): 11669. doi: 10.1038/s41598-017-11017-2
    [127]
    Suman SK, Daday C, Ferraro T, et al. The plakin domain of C. elegans VAB-10/plectin acts as a hub in a mechanotransduction pathway to promote morphogenesis[J]. Development, 2019, 146(24): dev183780. doi: 10.1242/dev.183780
    [128]
    Na S, Chowdhury F, Tay B, et al. Plectin contributes to mechanical properties of living cells[J]. Am J Physiol Cell Physiol, 2009, 296(4): C868–C877. doi: 10.1152/ajpcell.00604.2008
    [129]
    Almeida FV, Walko G, McMillan JR, et al. The cytolinker plectin regulates nuclear mechanotransduction in keratinocytes[J]. J Cell Sci, 2015, 128(24): 4475–4486. doi: 10.1242/jcs.173435
    [130]
    Wintner O, Hirsch-Attas N, Schlossberg M, et al. A unified linear viscoelastic model of the cell nucleus defines the mechanical contributions of lamins and chromatin[J]. Adv Sci (Weinh), 2020, 7(8): 1901222. doi: 10.1002/advs.201901222
    [131]
    Sapra KT, Qin Z, Dubrovsky-Gaupp A, et al. Nonlinear mechanics of lamin filaments and the meshwork topology build an emergent nuclear lamina[J]. Nat Commun, 2020, 11(1): 6205. doi: 10.1038/s41467-020-20049-8
    [132]
    Khilan AA, Al-Maslamani NA, Horn HF. Cell stretchers and the LINC complex in mechanotransduction[J]. Arch Biochem Biophys, 2021, 702: 108829. doi: 10.1016/j.abb.2021.108829
    [133]
    Sun J, Groppi VE, Gui H, et al. High-throughput screening for drugs that modulate intermediate filament proteins[J]. Methods Enzymol, 2016, 568: 163–185. https://pubmed.ncbi.nlm.nih.gov/26795471/
    [134]
    Sharma P, Alsharif S, Fallatah A, et al. Intermediate filaments as effectors of cancer development and metastasis: a focus on keratins, vimentin, and nestin[J]. Cells, 2019, 8(5): 497. doi: 10.3390/cells8050497
    [135]
    Nakamura F, Song M, Hartwig JH, et al. Documentation and localization of force-mediated filamin A domain perturbations in moving cells[J]. Nat Commun, 2014, 5: 4656. doi: 10.1038/ncomms5656
    [136]
    Aragona M, Panciera T, Manfrin A, et al. A mechanical checkpoint controls multicellular growth through YAP/TAZ regulation by actin-processing factors[J]. Cell, 2013, 154(5): 1047–1059. doi: 10.1016/j.cell.2013.07.042
    [137]
    Nakamura F. The role of mechanotransduction in contact inhibition of locomotion and proliferation[J]. Int J Mol Sci, 2024, 25(4): 2135. doi: 10.3390/ijms25042135
    [138]
    Fallatah A, Anastasakis DG, Manzourolajdad A, et al. Keratin 19 binds and regulates cytoplasmic HNRNPK mRNA targets in triple-negative breast cancer[J]. BMC Mol Cell Biol, 2023, 24(1): 26. doi: 10.1186/s12860-023-00488-z
    [139]
    Kim SH, Kim S, Choi HI, et al. Callus formation is associated with hyperproliferation and incomplete differentiation of keratinocytes, and increased expression of adhesion molecules[J]. Br J Dermatol, 2010, 163(3): 495–501. doi: 10.1111/j.1365-2133.2010.09842.x
  • Related Articles

    [1]Liu Xiaowei, Nakamura Fumihiko. Mechanotransduction, nanotechnology, and nanomedicine[J]. The Journal of Biomedical Research, 2021, 35(4): 284-293. DOI: 10.7555/JBR.34.20200063
    [2]Tiwari-Heckler Shilpa, Jiang Z. Gordon, Popov Yury, J. Mukamal Kenneth. Daily high-dose aspirin does not lower APRI in the Aspirin-Myocardial Infarction Study[J]. The Journal of Biomedical Research, 2020, 34(2): 139-142. DOI: 10.7555/JBR.33.20190041
    [3]Tao Chun'ai, Gan Yongxin, Su Weidong, Li Zhutian, Tang Xiaolan. Effectiveness of hospital disinfection and experience learnt from 11 years of surveillance[J]. The Journal of Biomedical Research, 2019, 33(6): 408-413. DOI: 10.7555/JBR.33.20180118
    [4]Vetrivel Preethi, Kim Seong Min, Saralamma Venu Venkatarame Gowda, Ha Sang Eun, Kim Eun Hee, Min Tae Sun, Kim Gon Sup. Function of flavonoids on different types of programmed cell death and its mechanism: a review[J]. The Journal of Biomedical Research, 2019, 33(6): 363-370. DOI: 10.7555/JBR.33.20180126
    [5]Huan Liu, Shijiang Zhang, Yongfeng Shao, Xiaohu Lu, Weidong Gu, Buqing Ni, Qun Gu, Junjie Du. Biomechanical characterization of a novel ring connector for sutureless aortic anastomosis[J]. The Journal of Biomedical Research, 2018, 32(6): 454-460. DOI: 10.7555/JBR.31.20170011
    [6]Minbo Zang, Qiao Zhou, Yunfei Zhu, Mingxi Liu, Zuomin Zhou. Effects of chemotherapeutic agent bendamustine for nonhodgkin lymphoma on spermatogenesis in mice[J]. The Journal of Biomedical Research, 2018, 32(6): 442-453. DOI: 10.7555/JBR.31.20170023
    [7]Kaibo Lin, Shikun Zhang, Jieli Chen, Ding Yang, Mengyi Zhu, Eugene Yujun Xu. Generation and functional characterization of a conditional Pumilio2 null allele[J]. The Journal of Biomedical Research, 2018, 32(6): 434-441. DOI: 10.7555/JBR.32.20170117
    [8]Huanqiang Wang, Congying Yang, Siyuan Wang, Tian Wang, Jingling Han, Kai Wei, Fucun Liu, Jida Xu, Xianzhen Peng, Jianming Wang. Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer[J]. The Journal of Biomedical Research, 2018, 32(6): 424-433. DOI: 10.7555/JBR.32.20170065
    [9]Fengzhen Wang, Mingwan Zhang, Dongsheng Zhang, Yuan Huang, Li Chen, Sunmin Jiang, Kun Shi, Rui Li. Preparation, optimization, and characterization of chitosancoated solid lipid nanoparticles for ocular drug delivery[J]. The Journal of Biomedical Research, 2018, 32(6): 411-423. DOI: 10.7555/JBR.32.20160170
    [10]Christopher J. Danford, Zemin Yao, Z. Gordon Jiang. Non-alcoholic fatty liver disease: a narrative review of genetics[J]. The Journal of Biomedical Research, 2018, 32(6): 389-400. DOI: 10.7555/JBR.32.20180045

Catalog

    Corresponding author: Fumihiko Nakamura, fnakamura@tju.edu.cn

    1. On this Site
    2. On Google Scholar
    3. On PubMed

    Figures(1)

    Article Metrics

    Article views (601) PDF downloads (75) Cited by()
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return